Leerink Partners Assumes Kymera Therapeutics (KYMR) at Outperform, 'We have a more cautious view on KT-474'
Tweet Send to a Friend
(Updated - September 9, 2024 12:07 PM EDT)
Leerink Partners analyst Faisal Khurshid assumes coverage on Kymera Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst Faisal Khurshid assumes coverage on Kymera Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
